These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2788491)

  • 1. Interleukin-2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers.
    Baker H; Marcus SL; Frank O; Petrylak DP; DeAngelis B; Dutcher JP; Wiernik PH
    Cancer; 1989 Sep; 64(6):1226-31. PubMed ID: 2788491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
    Koretz MJ; Lawson DH; York RM; Graham SD; Murray DR; Gillespie TM; Levitt D; Sell KM
    Arch Surg; 1991 Jul; 126(7):898-903. PubMed ID: 1854252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis with adoptive immunotherapy using LAK cells and IL-2].
    Usui A
    Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1058-64. PubMed ID: 2214469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
    J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
    Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An explanation of the variable clinical response to interleukin 2 and LAK cells.
    Parmiani G
    Immunol Today; 1990 Apr; 11(4):113-5. PubMed ID: 2187466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lymphokine-activated killer cell adoptive immunotherapy for cancer treatment and its significance].
    Toge T; Yamaguchi Y
    Hum Cell; 1992 Sep; 5(3):218-25. PubMed ID: 1334695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.
    Wang J; Walle A; Gordon B; Novogrodsky A; Suthanthiran M; Rubin AL; Morrison H; Silver RT; Stenzel KH
    Am J Med; 1987 Dec; 83(6):1016-23. PubMed ID: 2845776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adoptive immunotherapy with interleukin 2. Initial results of a pilot study in 6 cancer patients].
    Sculier JP; Bron D; Delforge A; Body JJ; Verboven N; Frühling J; Stryckmans P; Klastersky J
    Presse Med; 1989 Jun; 18(23):1155-8. PubMed ID: 2525748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy using lymphokine-activated killer cells.
    Fowler JE
    J Urol; 1988 Jan; 139(1):148-9. PubMed ID: 3257273
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M
    Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new approach in the treatment of metastatic melanoma: adoptive immunotherapy using lymphokine-activated killer cells and interleukin 2].
    Keilholz U; Welters H; Dummer R; Tilgen W; Hunstein W
    Hautarzt; 1988 Jun; 39(6):378-81. PubMed ID: 3261288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apheresis techniques in lymphokine-activated killer cell production.
    Sniecinski I; Sentinella K; Margolin K; Mills B
    J Clin Apher; 1988; 4(2-3):108-12. PubMed ID: 3260897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.